摘要
雷诺嗪于2006年作为抗心绞痛药物被美国食品和药物管理局(FDA)批准。随着多项临床试验的开展,雷诺嗪也被证实在房性和室性心律失常的预防和治疗上有效,并对于肺动脉高压的治疗有一些探索性的研究。本文就雷诺嗪的药理学特点及其近年来在心血管疾病方面的临床应用进展做一综述。
Ranolazine was approved by the U.S. Food and Drug Administration in 2006 as an anti- anginal agent. With the development of serial clinical trials, ranolazine has also been demonstrated effectiveness in the prevention and treatment of atrial and ventricular arrhythmias. Some exploratory trials have proved ranolazine had the therapy potential for pulmonary arterial hypertension. The pharmacological characteristics of ranolazine and its development in the clinical application for cardiovascular diseases were reviewed in this articIe.
出处
《中国新药与临床杂志》
CSCD
北大核心
2017年第6期314-319,共6页
Chinese Journal of New Drugs and Clinical Remedies
关键词
雷诺嗪
心绞痛
抗心律失常药
高血压
肺性
ranolazine
angina pectoris
anti-arrhythmias agents
hypertension, pulmonary